MarketBeat Reports on Hyperfine's Standing Against Healthcare Competitors
1 report, 1 independent
Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat compared Hyperfine to 511 publicly-traded companies in the Healthcare Equipment & Supplies industry. The report noted that 15.0% of Hyperfine shares are held by institutional investors, which is lower than the 40.5% average for the industry. Hyperfine also has a consensus target price of $2.02, indicating a potential upside of 184.69%.
From themarketsdaily.com
Why it matters
Equities research analysts believe Hyperfine is more favorable than its competitors due to its stronger consensus rating and higher probable upside. Furthermore, Hyperfine's share price is 49% more volatile than the S&P 500, as indicated by a beta of 1.49.
From themarketsdaily.com
Who's involved
- MarketBeatProvides financial tracking and consensus rating data
- NasdaqIs the stock exchange where publicly traded companies are listed
- Northland PowerUtilizes MarketBeat for financial tracking
- Arbutus BiopharmaUtilizes MarketBeat as its financial data reporting platform
- AppFolioProvides data and analyst ratings aggregated by MarketBeat